|
1
|
Albihn A, Johnsen JI and Henriksson MA:
MYC in oncogenesis and as a target for cancer therapies. Adv Cancer
Res. 107:163–224. 2010.PubMed/NCBI
|
|
2
|
Chen Y and Olopade OI: MYC in breast tumor
progression. Expert Rev Anticancer Ther. 8:1689–1698. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wolfer A and Ramaswamy S: MYC and
metastasis. Cancer Res. 71:2034–2037. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wolfer A, Wittner BS, Irimia D, et al: MYC
regulation of a ‘poor-prognosis’ metastatic cancer cell state. Proc
Natl Acad Sci USA. 107:3698–3703. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rodriguez-Pinilla SM, Jones RL, Lambros
MB, et al: MYC amplification in breast cancer: a chromogenic in
situ hybridisation study. J Clin Pathol. 60:1017–1023. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Todorović-Raković N,
Nešković-Konstantinović Z and Nikolić-Vukosavljević D: C-myc as a
predictive marker for chemotherapy in metastatic breast cancer.
Clin Exp Med. 12:217–223. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Joensuu K, Hagström J, Leidenius M,
Haglund C, Andersson LC, Sariola H and Heikkilӓ P: Bmi-1, c-myc,
and Snail expression in primary breast cancers and their metastases
- elevated Bmi-1 expression in late breast cancer relapses.
Virchows Arch. 459:31–39. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Planas-Silva MD, Bruggeman RD, Grenko RT
and Smith JS: Overexpression of c-Myc and Bcl-2 during progression
and distant metastasis of hormone-treated breast cancer. Exp Mol
Pathol. 82:85–90. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Singhi AD, Cimino-Mathews A, Jenkins RB,
et al: MYC gene amplification is often acquired in lethal distant
breast cancer metastases of unamplified primary tumors. Mod Pathol.
25:378–387. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kalluri R and Zeisberg M: Fibroblasts in
cancer. Nat Rev Cancer. 6:392–401. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gouvêa AP, Milanezi F, Olson SJ, Leitao D,
Schmitt FC and Gobbi H: Selecting antibodies to detect HER2
overexpression by immunohistochemistry in invasive mammary
carcinomas. Appl Immunohistochem Mol Morphol. 14:103–108. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Allred DC and Elledge RM: Caution
concerning micrometastatic breast carcinoma in sentinel lymph
nodes. Cancer. 86:905–907. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nielsen TO, Hsu FD, Jensen K, et al:
Immunohistochemical and clinical characterization of the basal-like
subtype of invasive breast carcinoma. Clin Cancer Res.
10:5367–5374. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Carey LA, Perou CM, Livasy CA, et al:
Race, breast cancer subtypes, and survival in the Carolina Breast
Cancer Study. JAMA. 295:2492–2502. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tobler NE and Detmar M: Tumor and lymph
node lymphangiogenesis - impact on cancer metastasis. J Leukoc
Biol. 80:691–696. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cao Y: Opinion: emerging mechanisms of
tumour lymphangiogenesis and lymphatic metastasis. Nat Rev Cancer.
5:735–743. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chambers AF, Groom AC and MacDonald IC:
Dissemination and growth of cancer cells in metastatic sites. Nat
Rev Cancer. 2:563–572. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ellsworth RE, Ellsworth DL, Patney HL,
Deyarmin B, Hooke JA, Love B and Shriver CD: Genomic alterations
associated with early stages of breast tumor metastasis. Ann Surg
Oncol. 15:1989–1995. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
O'Connell JT, Sugimoto H, Cooke VG, et al:
VEGF-A and tenascin-C produced by S100A4+ stromal cells are
important for metastatic colonization. Proc Natl Acad Sci USA.
108:16002–16007. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hasebe T, Sasaki S, Imoto S and Ochiai A:
Proliferative activity of intratumoral fibroblasts is closely
correlated with lymph node and distant organ metastases of invasive
ductal carcinoma of the breast. Am J Pathol. 156:1701–1710. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ostano P, Bione S, Belgiovine C, et al:
Cross-analysis of gene and miRNA genome-wide expression profiles in
human fibroblasts at different stages of transformation. OMICS.
16:24–36. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chrzan P, Skokowski J, Karmolinski A and
Pawelczyk T: Amplification of c-myc gene and overexpression of
c-Myc protein in breast cancer and adjacent non-neoplastic tissue.
Clin Biochem. 34:557–562. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Blancato J, Singh B, Liu A, Liao DJ and
Dickson RB: Correlation of amplification and overexpression of the
c-myc oncogene in high-grade breast cancer: FISH, in situ
hybridisation and immunohistochemical analyses. Br J Cancer.
90:1612–1619. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Naidu R, Wahab NA, Yadav M and Kutty MK:
Protein expression and molecular analysis of c-myc gene in primary
breast carcinomas using immunohistochemistry and differential
polymerase chain reaction. Int J Mol Med. 9:189–196.
2002.PubMed/NCBI
|
|
25
|
Spandidos DA, Yiagnisis M, Papadimitriou K
and Field JK: ras, c-myc and c-erbB-2 oncoproteins in human breast
cancer. Anticancer Res. 9:1385–1393. 1989.PubMed/NCBI
|
|
26
|
Zongaro S, de Stanchina E, Colombo T,
D'Incalci M, Giulotto E and Mondello C: Stepwise neoplastic
transformation of a telomerase immortalized fibroblast cell line.
Cancer Res. 65:11411–11418. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Musgrove EA, Sergio CM, Loi S, et al:
Identification of functional networks of estrogen- and
c-Myc-responsive genes and their relationship to response to
tamoxifen therapy in breast cancer. PLoS One. 3:e29872008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Miller TW, Balko JM, Ghazoui Z, et al: A
gene expression signature from human breast cancer cells with
acquired hormone independence identifies MYC as a mediator of
antiestrogen resistance. Clin Cancer Res. 17:2024–2034. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chandriani S, Frengen E, Cowling VH,
Pendergrass SA, Perou CM, Whitfield ML and Cole MD: A core MYC gene
expression signature is prominent in basal-like breast cancer but
only partially overlaps the core serum response. PLoS One.
4:e66932009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yasojima H, Shimomura A, Naoi Y, et al:
Association between c-myc amplification and pathological complete
response to neoadjuvant chemotherapy in breast cancer. Eur J
Cancer. 47:1779–1788. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Alles MC, Gardiner-Garden M, Nott DJ, et
al: Meta-analysis and gene set enrichment relative to ER status
reveal elevated activity of MYC and E2F in the ‘basal’ breast
cancer subgroup. PLoS One. 4:e47102009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Doe MR, Ascano JM, Kaur M and Cole MD: Myc
posttranscriptionally induces HIF1 protein and target gene
expression in normal and cancer cells. Cancer Res. 72:949–957.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Baudino TA, McKay C, Pendeville-Samain H,
et al: c-Myc is essential for vasculogenesis and angiogenesis
during development and tumor progression. Genes Dev. 16:2530–2543.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dang CV, Le A and Gao P: MYC-induced
cancer cell energy metabolism and therapeutic opportunities. Clin
Cancer Res. 15:6479–6483. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pavlides S, Whitaker-Menezes D,
Castello-Cros R, et al: The reverse Warburg effect: aerobic
glycolysis in cancer associated fibroblasts and the tumor stroma.
Cell Cycle. 8:3984–4001. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Falck AK, Fernö M, Bendahl PO and Rydén L:
Does analysis of biomarkers in tumor cells in lymph node metastases
give additional prognostic information in primary breast cancer?
World J Surg. 34:1434–1441. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Aitken SJ, Thomas JS, Langdon SP, Harrison
DJ and Faratian D: Quantitative analysis of changes in ER, PR and
HER2 expression in primary breast cancer and paired nodal
metastases. Ann Oncol. 21:1254–1261. 2010. View Article : Google Scholar : PubMed/NCBI
|
